Noctamid Tablets 1mg

  • Name:

    Noctamid Tablets 1mg

  • Company:
    info
  • Active Ingredients:

    Lormetazepam

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 30/08/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 30/8/2019

Click on this link to Download PDF directly

Bayer Limited

Bayer Limited

Company Products

Medicine NameActive Ingredients
Medicine Name Adalat LA 20 Active Ingredients Nifedipine
Medicine Name Adalat LA 30 Active Ingredients Nifedipine
Medicine Name Adalat LA 60 Active Ingredients Nifedipine
Medicine Name Alka Seltzer Effervescent Tablets Active Ingredients Acetylsalicylic acid (Aspirin), Citric Acid, Sodium Hydrogen Carbonate
Medicine Name Androcur 100 Active Ingredients Cyproterone Acetate
Medicine Name Angeliq 1 mg / 2 mg film-coated tablets Active Ingredients Drospirenone, Estradiol Hemihydrate
Medicine Name Aspirin 300mg Effervescent Tablets Active Ingredients Acetylsalicylic acid (Aspirin)
Medicine Name Avelox 400mg Film-coatedTablets Active Ingredients Moxifloxacin hydrochloride
Medicine Name Avelox 400mg/250ml Solution for Infusion Active Ingredients Moxifloxacin hydrochloride
Medicine Name Bepantiseptic First Aid Cream Active Ingredients Chlorhexidine digluconate, Phenol
Medicine Name Betaferon 250 microgram/ml, powder and solvent for solution for injection Active Ingredients Interferon beta-1b
Medicine Name Canesten 200mg Pessary Active Ingredients Clotrimazole
Medicine Name Canesten 500mg Pessary Active Ingredients Clotrimazole
Medicine Name Canesten Combi Pessary and Cream Active Ingredients Clotrimazole
Medicine Name Canesten Cream Active Ingredients Clotrimazole
Medicine Name Canesten Duopak Active Ingredients Clotrimazole
Medicine Name Canesten HC Cream Active Ingredients Clotrimazole, Hydrocortisone
Medicine Name Canesten Soft Vaginal Capsule Combi Active Ingredients Clotrimazole
Medicine Name Canesten Thrush Cream Active Ingredients Clotrimazole
Medicine Name Ciproxin 250mg Film-coated Tablets Active Ingredients Ciprofloxacin hydrochloride
Medicine Name Ciproxin 500mg Film-coated Tablets Active Ingredients Ciprofloxacin hydrochloride
Medicine Name Ciproxin 750mg Film-coated Tablets Active Ingredients Ciprofloxacin hydrochloride
Medicine Name Ciproxin Solution for Infusion 2mg/ml, 200ml Active Ingredients Ciprofloxacin
Medicine Name Clarityn 10 mg Tablets Active Ingredients Loratadine
Medicine Name Cystopurin 3g Granules for Oral Solution Active Ingredients Potassium Citrate
1 - 0 of 74 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 30 August 2019 PIL

Reasons for updating

  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - excipient warnings
  • Change to section 6 - date of revision

Updated on 30 August 2019 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 11 March 2016 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 11 March 2016 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

 

text in red added:

For patients with
mild to moderate chronic respiratory insufficiency or hepatic insufficiency a dose reduction should be considered.

 

Updated on 5 January 2016 PIL

Reasons for updating

  • New PIL for new product

Updated on 5 January 2016 PIL

Reasons for updating

  • Change to dosage and administration

Updated on 17 December 2015 PIL

Reasons for updating

  • Change to date of revision
  • Change to name of manufacturer

Updated on 29 January 2015 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 28 January 2015 SmPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Update to section 4.8 to include HPRA reporting of adverse event text 

Updated on 9 January 2014 PIL

Reasons for updating

  • Change to, or new use for medicine
  • Change to warnings or special precautions for use
  • Change to drug interactions
  • Change to further information section
  • Change to date of revision
  • Change to dosage and administration
  • Change to improve clarity and readability
  • Addition of information on reporting a side effect.

Updated on 16 December 2013 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

- Updates throughout the SPC to align with the QRD template.
- Inclusion of information that patients with chronic respiratory insufficiency or hepatic insufficiency may need dose reductions to be considered, in section 4.2.
- Update of section 4.4 to include warnings for patients with hepatic impairment and that abuse of benzodiazepines has been reported.
- Update to section 4.5 detailing drugs for which drugs interactions have been observed.
- Update to section 4.8 with information on how to report an adverse effect.
- Update to section 5.2 with information on use in patient with liver cirrhosis.
- Update of revision date of the text.

Updated on 22 March 2013 SmPC

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.7 - Effects on ability to drive and use machines

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

A couple of sentences have been reinserted in two of the sections:

 

Section 4.5

Enhancement of the euphoria may also occur leading to an increased risk in psychic dependence.

The sedative effect may be enhanced when the product is used in combination with alcohol.

 

Section 4.7

Reactions can be particularly impaired due to insufficient sleep duration, individual sensitivity and dosage. This applies to an increased extent in association with alcohol.

 

Updated on 5 March 2013 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to side-effects
  • Change to drug interactions
  • Change to information about driving or using machinery
  • Change to date of revision

Updated on 28 January 2013 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.2
Additional information is included re duration of action.

Section 4.3

Deleted from section:

Rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption

 

Section 4.4

Included:

 

Patients with spinal and cerebellar ataxia

Noctamid should be administered with caution to patients with spinal and cerebellar ataxia.

 

Patients with severe hepatic insufficiency

There are limited pharmacokinetic data concerning single dosing of Noctamid in patients with mild to moderate hepatic insufficiency. The reduced plasma clearance in these patients leads to an average 2-fold increase of maximum concentration and systemic exposure (AUC). However, no pharmacokinetic data from clinical trials are available regarding repeated dosing of Noctamid in this patient population.

 

Excipients

This medicinal product contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine

 

Section 4.5

This section has been re-organised and editorial changes included.

 

Section 4.8

Additional text has been included re side effects and the table has been updated in particular in respect of side effects where the incidence is not known.

 

Section 5.1

An ATC code and therapeutic group have now been included.

Updated on 19 August 2011 PIL

Reasons for updating

  • Change to date of revision
  • Change to name of manufacturer

Updated on 7 December 2010 PIL

Reasons for updating

  • Change due to user-testing of patient information

Updated on 26 April 2010 PIL

Reasons for updating

  • Change to marketing authorisation holder

Updated on 4 September 2009 PIL

Reasons for updating

  • Change of manufacturer

Updated on 1 December 2008 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to date of revision
  • Change to improve clarity and readability

Updated on 16 September 2008 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

A subset of ‘4.4 Special warnings and precautions for use’ has been changed from:

 

4.4.6 Specific patient groups:

·         Noctamid should not be given to patients under 18 years of age without careful assessment of the need to do so: the duration of treatment must be kept to a minimum (see section ‘Posology and method of administration’).

·         Elderly patients should be given a reduced dose (see ‘Posology and method of administration’).

·         A lower dose is also recommended for patients with chronic respiratory insufficiency due to the risk of respiratory depression (see also ‘4.3 Contraindications’).

·         It is recommended to treat patients with severe hepatic insufficiency with caution, as benzodiazepines may enhance symptoms of encephalopathy.

·         Noctamid should be administered with caution to patients with severe renal insufficiency.

 

Myorelaxant effect:

Because of the myorelaxant effect there is a danger of falls and consequently of hip fractures for elderly patients on getting up at night.

 

To:

 

4.4.6 Specific patient groups:

Paediatric patients

Noctamid should not be given to patients under 18 years of age without careful assessment of the need to do so. The duration of treatment must be kept to a minimum (see section 4.2 ‘Posology and method of administration’).

 

Elderly

Benzodiazepines may be associated with an increased risk of falling due to adverse effects including ataxia, muscle weakness, dizziness, somnolence/sleepiness, fatigue and therefore it is recommended to treat elderly patients with particular caution.

 

Elderly patients should be given a reduced dose (see section 4.2 ‘Posology and method of administration’).

 

Patients with chronic respiratory insufficiency

A lower dose is also recommended for patients with chronic respiratory insufficiency due to the risk of respiratory depression (see also section 4.3 ‘Contraindications’).

 

Patients with severe hepatic insufficiency

It is recommended to treat patients with severe hepatic insufficiency with caution, as benzodiazepines may enhance symptoms of encephalopathy.

 

Patients with severe renal insufficiency

Noctamid should be administered with caution to patients with severe renal insufficiency.

 

‘4.8 Undesirable effects’ has been changed from:

 

Psychiatric and ‘paradoxical’ reactions:

Reactions like restlessness, agitation, irritability, aggressiveness, delusion, rages, nightmares, psychoses, inappropriate abnormal behaviour and other adverse behaviour disorders are known to occur when using Noctamid. Should this occur, use of the product should be discontinued.

These reactions are more likely to occur in children and the elderly, as well as in patients with organic brain syndrome.

Noctamid is not recommended for the primary treatment of psychotic illness. It should not be used alone for the treatment of sleep disorders associated with depression. Pre-existing depression may be unmasked during benzodiazepine use. Suicide may be precipitated in such patients.

 

To:

 

Psychiatric and ‘paradoxical’ reactions:

Reactions like restlessness, agitation, irritability, aggressiveness, delusion, rages, nightmares, hallucinations, psychoses, inappropriate abnormal behaviour and other adverse behaviour disorders are known to occur when using Noctamid. Should this occur, use of the product should be discontinued.

These reactions are more likely to occur in children and the elderly, as well as in patients with organic brain syndrome.

Noctamid is not recommended for the primary treatment of psychotic illness. It should not be used alone for the treatment of sleep disorders associated with depression. Pre-existing depression may be unmasked during benzodiazepine use. Suicide may be precipitated in such patients.

 

 The revision date has been changed to August 2008.

Updated on 14 May 2008 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - MA number
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

2. Qualitative and Quantitative Composition

This section was amended to include the following statement:

Excipient: Contains 71mg lactose (as monohydrate)

‘For excipients, see section 6.1’ was changed to ‘For a full list of excipients, see section 6.1’.

 

3. Pharmaceutical Form

The following statement was included: The tablet can be divided into equal halves.

 

7. Marketing Authorisation Holder

The PA Holder name and address was changed from Bayer UK following transfer of the product to:

Bayer Limited

The Atrium

Blackthorn Road

Dublin 18

 

8. Marketing Authorisation Number(s)

PA 1410/9/1 replaces the old number PA 12/51/2

 

9. Date of First Authorisation/Renewal of the Authorisation

This section now reflects the renewal of the PA at the beginning of November 2007:

1 November 1982/1 November 2007

 

 

10. Date of Revision of the Text

November 2007

 

Updated on 30 April 2008 PIL

Reasons for updating

  • Change to marketing authorisation holder
  • Change to date of revision

Updated on 12 April 2007 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to instructions about missed dose
  • Change to instructions about overdose
  • Change to side-effects
  • Change to drug interactions
  • Change to information about drinking alcohol
  • Change to information about pregnancy or lactation
  • Change to information about driving or using machinery
  • Change to how the medicine works
  • Change to dosage and administration

Updated on 12 April 2007 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Main Changes to the SPC include:

 

Section 4.2 Posology and method of administration

Updated:

-         Dose recommendations in adult and elderly patients

-         Recommendations for use in patients under 18 years of age

 

Recommendations for duration of treatment are now included in Section 4.4.

 

Section 4.3 Contraindications

Update of contraindications in line with the most recent safety information.

Deletion of the following contra-indication:

-         Severe hepatic insufficiency

 

Additional contra-indication:

-         Hypersensitivity to any of the excipients

 

Section 4.4 Special warnings and precautions for use

Revised/additional text regarding:

-         Withdrawal reactions

-         Psychiatric and ‘paradoxical’ reactions

-         Use in patients with severe hepatic and renal insufficiency

 

Section 4.8 Undesirable effects

Undesirable effects have been revised according to the most recently available information and have been tabulated according to the MedDRA System Organ Class affected and the frequency of occurrence.

 

Updated text in relation to: Dependence, Psychiatric disorders, Psychiatric and ‘paradoxical’ reactions, Nervous system disorders and Various system organ classes.

 

Section 4.9 Overdose

Revised information regarding the symptoms and treatment of Noctamid overdose.

 

Section 5.1 Pharmacodynamic properties

Text expanded in line with current knowledge of benzodiazepine activity.

 

Section 5.2 Pharmacokinetic properties

Section updated in line with most recently available information.

 

Section 5.3 Preclinical safety data

Section updated in line with most recently available information.

Updated on 13 September 2006 PIL

Reasons for updating

  • Change of manufacturer

Updated on 20 July 2006 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 7. Marketing Authorisation Holder
Change of address to 72 Heather Road, Dublin 18

Updated on 19 July 2006 PIL

Reasons for updating

  • Change to marketing authorisation holder

Updated on 23 November 2005 SmPC

Reasons for updating

  • Change to section 4.3 - Contraindications

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 23 November 2005 PIL

Reasons for updating

  • Change to warnings or special precautions for use

Updated on 4 October 2004 SmPC

Reasons for updating

  • Correction of spelling/typing errors

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 5 August 2004 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 9 July 2003 SmPC

Reasons for updating

  • Improved electronic presentation

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 2 July 2003 SmPC

Reasons for updating

  • Improved electronic presentation

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 11 June 2003 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may not be renewed (A)